June 2018

Contents

Editorial

• 29 June 2018: vol 19 no 11: darunavir/cobicistat alert and PK reports

• 08 June 2018: vol 19 no 10: DTG alert and PK reports

Treatment alerts

• New contraindication against using darunavir/cobicistat during pregnancy

• Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

• BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir

• ViiV Dear Doctor letter: Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception

Supplements

• Introduction to ART (May 2018)

Conference reports

• 19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore

• Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model

• Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole  

• Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network  

• Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults 

• No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin  

• Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin

• Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort

• 19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore

• Dolutegravir 50 mg twice daily sufficient with rifampicin but levels reduced significantly with 100 mg once daily 

• Vaginal ring reduces efavirenz but not atazanavir exposures 

• Dispersible paediatric versions of dolutegravir provide higher bioavailability than immediate release formulations  

Antiretrovirals

• China approves albuvirtide: a once-weekly injectable entry inhibitor

• Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance

• EMA approves dolutegravir/rilpivirine (Juluca) in Europe as dual-therapy HIV switch option

Side effects

• Boosted darunavir is associated with higher cardiovascular risk in D:A:D study, but not atazanavir

Coinfections and complications

• RITA: issue on lung health

HIV prevention and transmission

• New FDA guidance for developing PrEP drugs

• UK PrEP IMPACT trial announces 3000 new places for gay men but low uptake by women, African and transgender people

• Broad PrEP access in Australia reduces HIV infections even with reduced condom use by people not on PrEP

• Webcasts on PrEP and women

Cure-related research

• Cure research: open access publications

• Online database of more than 200 studies on HIV cure research

• Community survey on treatment interruptions (ATIs) in cure research

On the web

• US community call for coalition for long-term survivors

• Sexual identity and HIV

• Modern ART in Africa: new resources

PDFs

• 29 June 2018: vol 19 no 11

• 08 June 2018: vol 19 no 10